We are live on ! Find out more
NTGN

Neon Therapeutics, Inc. Common Stock
NTGN

Delisted

NTGN was delisted on the 5th of May, 2020.

46 hedge funds and large institutions have $18.6M invested in Neon Therapeutics, Inc. Common Stock in 2019 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 17 increasing their positions, 17 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

0% more repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 17

21% less funds holding

Funds holding: 5846 (-12)

34% less capital invested

Capital invested by funds: $28.4M → $18.6M (-$9.74M)

92% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 13

Holders
46
Holders Change
-12
Holders Change %
-20.69%
% of All Funds
0.91%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
1
Increased
17
Reduced
17
Closed
13
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
Marshall Wace
51
Marshall Wace
United Kingdom
-$38K -21,809 Closed
Squarepoint
52
Squarepoint
New York
-$35K -20,482 Closed
Jane Street
53
Jane Street
New York
-$32K -18,642 Closed
ARTA
54
A.R.T. Advisors
New York
-$22K -12,922 Closed
Ameriprise
55
Ameriprise
Minnesota
-$19K -11,205 Closed
WMSA
56
Weiss Multi-Strategy Advisers
New York
-$19K -11,000 Closed
Victory Capital Management
57
Victory Capital Management
Texas
-$4K -2,397 Closed
BCA
58
Berman Capital Advisors
Georgia
-$1K -684 Closed

NTGN Hedge Fund Activity: Q4 2019 in Review

46 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Neon Therapeutics, Inc. Common Stock (NTGN) for Q4 2019, worth a combined $18.6M — down 34% from $28.4M a quarter earlier.

Sellers outnumbered buyers: 13 funds closed out of NTGN and 1 opened new positions — a net loss of 12 holders — while 17 trimmed existing stakes and 17 added.

The largest buyer was Anson Funds Management, opening a new position worth an estimated $432K. The largest seller was Fidelity Investments, cutting an estimated $770K.

  • 46 institutional investors held Neon Therapeutics, Inc. Common Stock (NTGN) as of Q4 2019, down from 58 in Q3 2019.
  • Funds reported $18.6M of Neon Therapeutics, Inc. Common Stock stock for Q4 2019, down 34% quarter-over-quarter.
  • 1 fund opened new Neon Therapeutics, Inc. Common Stock positions in Q4 2019 and 13 closed out, a net change of -12 holders.
  • The largest Neon Therapeutics, Inc. Common Stock buyer in Q4 2019 was Anson Funds Management, an estimated $432K added.
  • The largest Neon Therapeutics, Inc. Common Stock seller in Q4 2019 was Fidelity Investments, an estimated $770K sold.

Based on aggregated 13F filings for Q4 2019.